Published: August 2022 | Report Code: 12441 | Available Format: PDF
The global downstream processing market revenue was valued at $21.1 billion in 2021, which is projected to advance at a CAGR of 10.3% during 2021–2030, to reach $51.0 billion by 2030. This is ascribed to factors such as the biotechnology sector expanding globally, rapid rise in R&D investment in the biopharmaceutical sector, and contract manufacturing organizations gaining significance. Furthermore, there have been incredible opportunities in the biotechnology industry, which have accelerated the expansion of the market on a global level.
Moreover, the rising demand for bioproducts, the growing adoption of biotech processes in the agricultural, pharmaceutical, and bio-services industries, the increasing adoption of single-use technology in bioprocessing, the surging advancements in the fields of gene therapy and genetic engineering, and the growing commercial success of biopharma companies are all contributing to the market growth. In addition, the increasing patent expiration of prominent biopharmaceuticals will generate new possibilities for the downstream processing industry throughout the forecast period.
The antibodies production category is expected to witness the fastest growth, advancing at a CAGR of around 10.9%, in the coming years, based on application. Because of the increased need for monoclonal antibodies (mAb), the demand for antibody manufacturing is surging at the highest rate. The introduction of new products for the effective purification of antibodies also drives the market growth in this category. For instance, in January 2021, Cytiva introduced HiScreen Fibro PrismA for the purification and process development of mAb.
Furthermore, antibodies have been identified as one of the most prevalent modalities for biopharmaceutical companies. The development of innovative technologies, such as alternative expression systems, continuous ongoing biomanufacturing, and nonchromatographic separation formats, for bioprocessing antibodies has accelerated the market expansion.
The chromatography systems category led the market and accounted for the largest revenue share, of 37.5%, in 2021, based on product. Continuous R&D operations to increase the efficiency and speed of chromatography systems are expected to drive market development. For instance, in April 2021, Thermo Fisher Scientific introduced the HyPeak chromatography system for bioprocessing, with important applications in therapeutic protein and vaccine production. Therefore, an increase in chromatographic system deals and innovations also augments the downstream processing market growth in this category.
The solid-liquid separation category is projected to witness the highest CAGR in the upcoming years. This is because the solid-liquid separation technique has various advantages, including cost-effectiveness, simplicity, and better-suited for continuous-mode production. Moreover, this type of filtration may also be easily applied to a wide range of pharmaceutical applications, due to its versatile nature.
Whereas, the purification by chromatography category accounted for the largest share in the market in 2021. This is ascribed to the high demand for extremely pure biopharmaceutical goods to fulfill regulatory standards, since downstream purification plays a vital role in improving product purity and quality, boosting the need for this purification technique.
As a result of the fast increase in R&D efforts relevant to advanced bioprocess technologies, high-throughput process development, perfusion chromatography systems, and continuous downstream processing systems for multicomponent separations, the high-resolution membrane systems have been widely adopted. This has led to the rise in the demand for better and advanced bioprocessing technologies for addressing the purification of a bottleneck.
The number of CMOs in the downstream processing industry has grown, as outsourcing assists pharmaceutical producers in lowering expensive initial capital investments and procedure expenses. In addition to cell culture preparation, chromatography, mixing, concentration, process monitoring, and disposable technologies, CMOs assist drug manufacturers in enhancing downstream purification processes. Conclusively, these factors are driving the downstream processing market growth.
Biopharmaceutical is one of the most promising areas in terms of future growth. Many healthcare organizations predict that this market will be one of the top 10 income sources in the coming years. Furthermore, corporations are making efforts to enhance their presence in this sector, in order to fulfill the rising demand for bio-based medicines, which results in increased biopharma companies’ accessibility for clinical use.
This consistent commercial success of biological pharmaceuticals is projected to propel the bioprocessing industry forward over the forecast period. Previously, only a few companies could handle the complete value chain of biologic manufacturing. This has changed considerably in recent years, since there are now multiple businesses in the market working in the development of biologics. Moreover, in recent years, the biological pharmaceutical business has expanded significantly to incorporate innovative product categories such as nanobody, rDNA, synthetic vaccine, fusion protein, soluble receptor, immunoconjugate, and immunotherapeutic. Therefore, the aforementioned factors are propelling the downstream processing market demand.
Market Size in 2021
$ 21.1 Billion
Revenue Forecast in 2030
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling
By Product; By Technique; By Application; By Region
Explore more about this report - Request free sample
APAC is projected to be the fastest-growing market and it would grow at a significant CAGR, of 10.8%, during the forecast period. This can be attributed to the improving R&D infrastructure, increasing expenditure made by market competitors, and rising government support.
On the other hand, North America led the market and accounted for the largest revenue share, of around 32.4%, in 2021. This is due to the rapid rise in government funding for bioprocess technologies, high medical costs, expanded healthcare infrastructure, and the presence of major market players in the region. Also, North America has seen involved in collaboration activities with healthcare behemoths that are heavily investing in the biopharma sector and vaccine R&D.
The market is fragmented with the presence of several players. These players have been involved in launching new products and acquiring similar companies, in order to stay ahead of their competitors. For instance:
The study offers a comprehensive market segmentation analysis along with market estimation for the period 2017-2030.
Based on Product Type
Based on Technique
Based on Application
The downstream processing market size stood at $21.1 million in 2021.
During 2021–2030, the growth rate of the downstream processing market will be around 10.3%.
Antibiotic Production is the largest application area in the downstream processing market.
The major drivers of the downstream processing market include the increasing adoption of biotech processes, the rising adoption of innovative technology in bioprocessing, and the surging commercial success of biopharmaceuticals.
Get a bespoke market intelligence solution
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws